Form 4: BDTX Director Prakash Raman Boosts Stock Holdings

Black Diamond Therapeutics Director Prakash Raman acquired 4,665 shares of common stock in lieu of cash compensation for his annual services.

Summary

• Prakash Raman, a Director of Black Diamond Therapeutics, Inc. (BDTX), acquired 4,665 shares of the company's common stock.
• The transaction occurred on December 12, 2025.
• These shares were issued as non-cash compensation for annual services as a non-employee director, in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• The price per share for the acquisition was $2.76, based on the closing market price on December 11, 2025.
• Following this transaction, Prakash Raman beneficially owns 31,027 shares of Black Diamond Therapeutics common stock.

Sentiment

Score: 6

Explanation: Slightly positive. While the shares were received as compensation, a director increasing their stake, even through non-cash means, can be viewed as a positive signal of commitment and alignment with shareholder interests.

Positives

• A director increasing their stake in the company, even through compensation, can signal confidence in the company's future prospects.
• The transaction aligns the director's financial interests more closely with those of the shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it is a report of a completed insider transaction.

Industry Context

Insider transactions, such as this director's stock acquisition, are routinely reported to the SEC. While this specific transaction is for compensation, it generally reflects a director's ongoing involvement and alignment with the company's performance, a common practice across publicly traded companies.

Comparison to Industry Standards

• The practice of compensating non-employee directors with equity is a standard corporate governance practice across many industries, including biotechnology, as it aligns director interests with long-term shareholder value.
• The reporting of such transactions via Form 4 is a standard regulatory requirement for all U.S. public companies, ensuring transparency in insider holdings.

Corporate Governance

Related Party Transactions

• The acquisition of common stock by Director Prakash Raman from Black Diamond Therapeutics, Inc. constitutes a related party transaction, as it involves a company insider and the issuer.

Stakeholder Impact

• Shareholders may view this transaction positively, as it demonstrates a director's continued investment in the company, potentially signaling confidence in its future performance.
• The transaction reinforces the company's commitment to its established non-employee director compensation policy.

Key Dates

Recommendation

A director's acquisition of shares, even as compensation, generally indicates alignment of interests and a degree of confidence in the company. However, a single Form 4 filing, without additional context from financial results or strategic updates, is typically not sufficient to warrant a strong buy or sell recommendation. It serves as a positive data point for existing holders.

Keywords

Black Diamond Therapeutics, BDTX, Prakash Raman, Insider Transaction, Form 4, Director Compensation, Stock Acquisition, Beneficial Ownership